



C WORLDWIDE BIOTECHNOLOGY (1A) AS OF 30 SEPTEMBER 2018

NET OF FEES IN EUR

STRATEGY

The investment objective of the C WorldWide Biotechnology fund is to achieve long-term capital growth by investing globally in a limited number of biotechnology companies. Investments are made in small and medium-sized fast-growing and research-intensive companies.


Our management team has a close collaboration with a scientific advisory board made up of leading scientists at the Karolinska Institute. This gives us unique insight into the forefront of medical research and valuable knowledge for example in evaluating the commercial potential of research projects.

Our investment decisions are based on thorough, fundamental equity research. This analysis is combined with dialogue with scientists as mentioned above and creates opportunities to put together a concentrated portfolio of 25-50 companies which we have detailed knowledge of, and which in our opinion constitute the most interesting investment opportunities in the long term.

TOP 10 HOLDINGS

	Share in %
Biogen	9.4 %
Vertex Pharmaceuticals	9.2 %
Gilead Sciences	8.5 %
Celgene	5.9 %
Alexion Pharmaceuticals	4.5 %
Biomarin Pharma	4.3 %
Sarepta Therapeutics	3.9 %
Incyte	3.8 %
Oncopeptides	3.5 %
Glaukos	2.7 %


INVESTMENT RETURNS




RETURN & RISK

	1 Y	3 Y	5 Y	10 Y	Lifetime	P.A.
Portfolio (%)	-1.3	8.1	53.6	291.4	209.6	6.5
Benchmark (%)	11.8	16.3	106.3	480.5	124.5	4.6
Relative performance (%)	-13.1	-8.2	-52.6	-189.1	85.1	1.9
		3 Y	5 Y	10 Y	Lifetime	P.A.
Std. dev. portfolio (%)		27.6	27.5	23.5	25.6	25.6
Std. dev. benchmark (%)		22.7	24.2	21.2	25.2	25.2
Beta		1.2	1.1	1.0	0.9	0.9

GEOGRAPHIC DIVERSIFICATION



SECTOR EXPOSURE



FACTS

Security identifier (ISIN):	LU0119485372
Launch date:	8 November 2000
Management fee:	1.10% per annum
Dealing frequency:	Daily
Base currency:	EUR
Minimum investment:	EUR 1,000
Benchmark:	NASDAQ Biotechnology Index®
NAV as of 30 September 2018:	30.96
Fund AUM:	13.1 million
Investment Manager:	C WorldWide Asset Management, Stockholm
Portfolio Manager:	Ulf Arvidsson, Angelica Fatouros, Mikael Svensson

DISCLAIMER

The fact sheet is for information purposes only. The fact sheet does not constitute, and shall not be considered as, an offer or invitation to purchase or sell any fund. The information, calculations etc. shall not be considered investment advice or requests to engage in investment operations.

All reasonable precautions have been taken to ensure the correctness and accuracy of the fact sheet. However, the correctness and accuracy is not guaranteed and C WorldWide Asset Management Fondsmæglerselskab A/S accepts no liability for any errors, spelling mistakes or omissions.

All figures are based on past performance. Past performance is not a reliable indicator of future performance. The currency is EUR. The return may increase or decrease as a result of currency fluctuations.

The figures are net of fees. Other fees, incurred by the investor, such as custody fees and transaction costs, are not included.

The NASDAQ Stock Market®, NASDAQ®, NASDAQ OMX®, and NASDAQ Biotechnology Index® are registered trademarks and trade names of The NASDAQ OMX Group, Inc. and are used with permission.